Literature DB >> 12809178

Interferon-alpha-induced transient severe hypothyroidism in a patient with Graves' disease.

M Braga-Basaria1, S Basaria.   

Abstract

Interferons (IFNs) are proteins with anti-viral activity and are widely used in the treatment of patients with chronic hepatitis C virus (HCV) infection. The use of IFNs has resulted in thyroid dysfunction in a variety of ways. We report a case of a woman with hyperthyroidism due to Graves' disease who developed significant hypothyroidism during treatment with IFN-alpha 2a for HCV infection. However, after discontinuation of IFN-alpha 2a, hyperthyroidism recurred. Potential mechanisms by which IFNs influence thyroid function are discussed.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12809178     DOI： 10.1007/BF03345167

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


  18 in total

Review 1.  Thyrotropin-receptor antibodies in thyroid diseases: advances in detection techniques and clinical applications.

Authors:  M K Gupta
Journal:  Clin Chim Acta       Date:  2000-03       Impact factor: 3.786

Review 2.  Interferons, a group of multiple lymphokines.

Authors:  H Kirchner
Journal:  Springer Semin Immunopathol       Date:  1984

3.  Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

4.  Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.

Authors:  A M Di Bisceglie; P Martin; C Kassianides; M Lisker-Melman; L Murray; J Waggoner; Z Goodman; S M Banks; J H Hoofnagle
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

5.  Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha.

Authors:  E Roti; R Minelli; T Giuberti; S Marchelli; C Schianchi; E Gardini; M Salvi; F Fiaccadori; G Ugolotti; T M Neri; L E Braverman
Journal:  Am J Med       Date:  1996-11       Impact factor: 4.965

6.  Thyroid function abnormalities associated with the chronic outpatient administration of recombinant interleukin-2 and recombinant interferon-alpha.

Authors:  E L Jacobs; M J Clare-Salzler; I J Chopra; R A Figlin
Journal:  J Immunother (1991)       Date:  1991-12

7.  Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C.

Authors:  E Baudin; P Marcellin; M Pouteau; N Colas-Linhart; J P Le Floch; C Lemmonier; J P Benhamou; B Bok
Journal:  Clin Endocrinol (Oxf)       Date:  1993-12       Impact factor: 3.478

8.  Autoimmune endocrine disease induced by recombinant interferon-alpha therapy for chronic active type C hepatitis.

Authors:  A Imagawa; N Itoh; T Hanafusa; Y Oda; M Waguri; J Miyagawa; N Kono; M Kuwajima; Y Matsuzawa
Journal:  J Clin Endocrinol Metab       Date:  1995-03       Impact factor: 5.958

9.  Fluctuating thyroid function depending on the balance between stimulating and blocking types of TSH receptor antibodies: a case report.

Authors:  K Kasagi; A Hidaka; K Endo; S Miyamoto; R Takeuchi; T Misaki; H Sakahara; J Konishi
Journal:  Thyroid       Date:  1993       Impact factor: 6.568

10.  Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a.

Authors:  D Preziati; L La Rosa; G Covini; R Marcelli; S Rescalli; L Persani; E Del Ninno; P L Meroni; M Colombo; P Beck-Peccoz
Journal:  Eur J Endocrinol       Date:  1995-05       Impact factor: 6.664
View more
  4 in total

Review 1.  Drug-induced endocrine and metabolic disorders.

Authors:  Ronald C W Ma; Alice P S Kong; Norman Chan; Peter C Y Tong; Juliana C N Chan
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 2.  Thyroid dysfunctions secondary to cancer immunotherapy.

Authors:  P Chalan; G Di Dalmazi; F Pani; A De Remigis; A Corsello; P Caturegli
Journal:  J Endocrinol Invest       Date:  2017-12-13       Impact factor: 4.256

3.  A quantitative assessment of depression and thyroid dysfunction secondary to interferon-alpha therapy in patients with hepatitis C.

Authors:  J M Loftis; J M Wall; E Linardatos; S Benvenga; P Hauser
Journal:  J Endocrinol Invest       Date:  2004 Jul-Aug       Impact factor: 4.256

4.  Interferon-alpha induced and ribavirin induced thyroid dysfunction in patients with chronic hepatitis C.

Authors:  Amina Nadeem; Muhammad Mazhar Hussain; Muhammad Aslam; Tassawar Hussain
Journal:  Hepat Mon       Date:  2010-06-01       Impact factor: 0.660
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.